Trials / Recruiting
RecruitingNCT06947993
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 224 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Detailed description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD. The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GHZ339 | GHZ339 administered at dose A, B, C and D |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2025-05-16
- Primary completion
- 2028-11-27
- Completion
- 2028-12-22
- First posted
- 2025-04-27
- Last updated
- 2025-12-22
Locations
99 sites across 17 countries: United States, Argentina, Canada, China, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Poland, Slovakia, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06947993. Inclusion in this directory is not an endorsement.